These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10485083)

  • 1. Note: caution in use of empirical equations for pharmacodynamic indirect response models.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Dec; 26(6):735-41. PubMed ID: 10485083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the dose-dependent time of peak effect in indirect response models.
    Majumdar A
    J Pharmacokinet Biopharm; 1998 Apr; 26(2):183-206. PubMed ID: 9795881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fit fluctuating blood drug concentration: a beginner's first note.
    Wu G
    Pharmacol Res; 1996 Jun; 33(6):379-83. PubMed ID: 8971962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):107-23. PubMed ID: 9353696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Aug; 26(4):385-408. PubMed ID: 10214559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic models: parameterizing the hill equation, Michaelis-Menten, the logistic curve, and relationships among these models.
    Reeve R; Turner JR
    J Biopharm Stat; 2013 May; 23(3):648-61. PubMed ID: 23611201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis.
    Bourne DW
    Comput Methods Programs Biomed; 1989 Jul; 29(3):191-5. PubMed ID: 2776455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of four basic models of indirect pharmacodynamic responses.
    Sharma A; Jusko WJ
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):611-35. PubMed ID: 9300353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics.
    Gabrielsson J; Andersson K; Tobin G; Ingvast-Larsson C; Jirstrand M
    Comput Methods Programs Biomed; 2014 Mar; 113(3):815-29. PubMed ID: 24461798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models.
    Lin S; Chien YW
    J Pharm Pharmacol; 2002 Jun; 54(6):791-800. PubMed ID: 12078995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.
    Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):179-204. PubMed ID: 21107661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic indirect response models characterize diverse types of pharmacodynamic effects.
    Jusko WJ; Ko HC
    Clin Pharmacol Ther; 1994 Oct; 56(4):406-19. PubMed ID: 7955802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Explicit solutions for a class of indirect pharmacodynamic response models.
    Jordan P; Gieschke R
    Comput Methods Programs Biomed; 2005 Feb; 77(2):91-7. PubMed ID: 15652631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of baseline parameters in determining indirect pharmacodynamic responses.
    Sun YN; Jusko WJ
    J Pharm Sci; 1999 Oct; 88(10):987-90. PubMed ID: 10514344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hill equation: a review of its capabilities in pharmacological modelling.
    Goutelle S; Maurin M; Rougier F; Barbaut X; Bourguignon L; Ducher M; Maire P
    Fundam Clin Pharmacol; 2008 Dec; 22(6):633-48. PubMed ID: 19049668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework.
    Dahl SG; Aarons L; Gundert-Remy U; Karlsson MO; Schneider YJ; Steimer JL; Trocóniz IF
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):2-12. PubMed ID: 19686541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous pharmacokinetic and pharmacodynamic modeling.
    Colburn WA
    J Pharmacokinet Biopharm; 1981 Jun; 9(3):367-88. PubMed ID: 7288596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of empirical, semi-empirical and physically based models of soil hydraulic functions derived for bi-modal soils.
    Kutílek M; Jendele L; Krejca M
    J Contam Hydrol; 2009 Feb; 104(1-4):84-9. PubMed ID: 19022525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.